AstraZeneca PLC (AZN)vs10X Genomics Inc (TXG)
AZN
AstraZeneca PLC
$156.45
-0.50%
HEALTHCARE · Cap: $243.86B
TXG
10X Genomics Inc
$56.09
-3.54%
HEALTHCARE · Cap: $7.31B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 9847% more annual revenue ($61.37B vs $616.91M). AZN leads profitability with a 17.0% profit margin vs -12.2%. AZN earns a higher WallStSmart Score of 65/100 (B-).
AZN
Strong Buy65
out of 100
Grade: B-
TXG
Avoid20
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+20.4%
Fair Value
$196.68
Current Price
$156.45
$40.23 discount
Margin of Safety
+65.9%
Fair Value
$56.16
Current Price
$56.09
$0.07 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Conservative balance sheet, low leverage
Areas to Watch
2.5% earnings growth
Distress zone — elevated risk
Trading at 8.9x book value
0.0% earnings growth
Weak financial health signals
ROE of -2.8% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.40 suggests the stock is reasonably priced for its growth.
Bull Case : TXG
The strongest argument for TXG centers on Debt/Equity.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Bear Case : TXG
The primary concerns for TXG are Price/Book, EPS Growth, Piotroski F-Score.
Key Dynamics to Monitor
AZN profiles as a mature stock while TXG is a turnaround play — different risk/reward profiles.
TXG carries more volatility with a beta of 2.04 — expect wider price swings.
AZN is growing revenue faster at 6.4% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (65/100 vs 20/100), backed by strong 17.0% margins. TXG offers better value entry with a 65.9% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
10X Genomics Inc
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and Asia Pacific. The company is headquartered in Pleasanton, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?